Puey Ling Chia

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Yi‐Long Wu, Valentina Guarneri, Pei Jye Voon et al. · The Lancet Oncology · 2024 · 70 citations · Full text

Met Amplification, Medicine, Pathology +8

An automated ECG classification system based on a neuro-fuzzy system

Hao Lu, Kok-Meng Ong, Puey Ling Chia · 2002 · 67 citations

Fuzzy Systems, Engineering, Intelligent Diagnostics +17

Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non–Small Cell Lung Cancer (NSCLC)

Puey Ling Chia, Thomas John · Journal of Immunotherapy · 2016 · 38 citations

Immunology, Dermatology, Immunotherapy +16

Predicting Students’ Academic Performances – A Learning Analytics Approach using Multiple Linear Regression

Olutayo Oyerinde, Puey Ling Chia · International Journal of Computer Applications · 2017 · 36 citations · Full text

Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment

Puey Ling Chia, Hongdo Do, Adrienne Morey et al. · Lung Cancer · 2016 · 27 citations

T790m Levels, Plasma Dna, Oncology +10